Search clinical trials for: TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyr

Total 17 results

PARZIBUT Gilles

Not yet recruiting

Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care (TRIMICU)

COPD Exacerbation
AstraZeneca
Parexel

Completed

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

Chronic Obstructive Pulmonary Disease - COPD

United States
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
Chiesi Farmaceutici S.p.A.

Completed

Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children (PAED3)

Asthma

Poland, Ukraine
Chiesi Farmaceutici S.p.A.

Active, not recruiting

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid (FORCE2)

Asthma

United States
The First Affiliated Hospital of Guangzhou Medical...
Guangdong Provincial Hospital of Traditional Chinese Medicine; Tongji Hospital and other collaborators

Not yet recruiting

Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (CC-ICS)

Cough

China
Sunovion

Completed

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | Emphysema | Bronchitis

United States
Sunovion

Completed

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Alfredo Antonio Chetta
University of Parma

Completed

The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.

Chronic Obstructive Pulmonary Disease

Italy
University Hospital, Antwerp
Chiesi Farmaceutici S.p.A.

Completed

Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients

Asthma

Belgium
Chiesi SA/NV

Completed

Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting (TRIVOLVE)

Chronic Obstructive Pulmonary Disease

Belgium
Chiesi SAS
Kappa Santé

Recruiting

Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study (TriNEXT)

COPD

France
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Research in Real-Life Ltd
Chiesi Farmaceutici S.p.A.

Completed

Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management (Fos/Ser_switch)

Asthma

United Kingdom
Sunovion

Completed

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Emphysema | Bronchitis

United States
Chiesi Farmaceutici S.p.A.

Completed

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) (FLASH)

Asthma

United States
Chiesi Farmaceutici S.p.A.

Recruiting

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON)

COPD | COPD Exacerbation

United States, Bulgaria, Hungary, Poland, Argentina, Czechia, Mexico, Canada, Puerto Rico, Romania

3

Subscribe